Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Monday, August 11th. HC Wainwright analyst R. Burns expects that the company will earn ($0.24) per share for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics' Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at $0.33 EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS and Q4 2026 earnings at ($0.27) EPS.
Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.06.
BDTX has been the topic of several other reports. Raymond James Financial upgraded shares of Black Diamond Therapeutics to an "outperform" rating and set a $11.00 price objective on the stock in a report on Tuesday, July 1st. Wall Street Zen lowered shares of Black Diamond Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $12.40.
Read Our Latest Report on Black Diamond Therapeutics
Black Diamond Therapeutics Price Performance
Shares of BDTX stock opened at $2.77 on Thursday. The firm has a market cap of $157.72 million, a P/E ratio of 12.04 and a beta of 2.87. Black Diamond Therapeutics has a 1-year low of $1.20 and a 1-year high of $6.75. The firm's 50-day simple moving average is $2.64 and its 200-day simple moving average is $2.15.
Institutional Trading of Black Diamond Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of BDTX. R Squared Ltd acquired a new stake in Black Diamond Therapeutics during the 2nd quarter worth approximately $25,000. Cerity Partners LLC acquired a new stake in Black Diamond Therapeutics in the second quarter valued at approximately $26,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Black Diamond Therapeutics in the second quarter valued at approximately $28,000. American Century Companies Inc. purchased a new position in shares of Black Diamond Therapeutics during the 2nd quarter valued at approximately $30,000. Finally, Jump Financial LLC purchased a new position in shares of Black Diamond Therapeutics during the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 95.47% of the company's stock.
About Black Diamond Therapeutics
(
Get Free Report)
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Black Diamond Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Black Diamond Therapeutics wasn't on the list.
While Black Diamond Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access